Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Korsana Biosciences, Inc. (KRSA)

Korsana Biosciences Q3 2026 net loss widens to $46.4 million after Cyclerion merger

Mixed Impact 4 of 5 earnings Written later

Korsana Biosciences reported its third quarter 2026 results on November 5, 2026, with a net loss of $46.4 million, up from $21.7 million a year earlier, as research and development expenses rose to $42.1 million. The company completed its merger with Cyclerion Therapeutics and a concurrent $380 million private placement in September 2026, and had $456.2 million in cash and cash equivalents at September 30, 2026, which it expects to fund operations into 2029.

Key points

  • Net loss of $46.4 million for Q3 2026, versus $21.7 million in Q3 2025; net loss per common share of $3.19, versus $39.49 a year earlier
  • R&D expenses of $42.1 million and G&A expenses of $6.1 million for Q3 2026
  • Cash and cash equivalents of $456.2 million at September 30, 2026, expected to fund operations into 2029
  • KRSA-028 Phase 1 healthy volunteer data expected in mid-2027; preclinical poster scheduled for November 18, 2026 at CTAD 2026

The filing

CompanyKorsana Biosciences, Inc. (KRSA)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:05 AM ET
Accession number0001193125-26-448535

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.